Uses of immunoconjugates targeting CD138

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9289509
APP PUB NO 20110123554A1
SERIAL NO

12774705

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • IMMUNOGEN, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Aigner, Silke Frankenthal, DE 12 163
Bruecher, Christoph Eschborn, DE 18 205
Czeloth, Niklas Dreieich, DE 7 48
Daelken, Benjamin Frankfurt am Main, DE 24 227
Engling, Andre Frankfurt, DE 3 20
Haeder, Thomas Dreieichenhain, DE 6 22
Niemann, Gabriele Karlsruhe, DE 3 20
Osterroth, Frank Dietzenbach, DE 18 194
Schulz, Gregor Umkirch, DE 13 85
Uherek, Christoph Seligenstadt, DE 26 302
Wartenberg-Demand, Andrea Linden, DE 13 123
Zeng, Steffen Muenster, DE 8 71
Zuber, Chantal Frankfurt, DE 9 52

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 22, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00